Research programme: CAR-T anticancer therapeutics - Atossa Genetics

Drug Profile

Research programme: CAR-T anticancer therapeutics - Atossa Genetics

Alternative Names: TRAP CAR-T - Atossa Genetics

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Atossa Genetics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Research Breast cancer

Most Recent Events

  • 28 Dec 2017 Atossa Genetics plans to initiate studies administering TRAP CAR-T cell with microcatheters for Breast cancer in the second half of 2018
  • 02 Oct 2017 Research programme: CAR-T anticancer therapeutics - Atossa Genetics is available for licensing as of 02 Oct 2017. http://www.atossagenetics.com/
  • 02 Oct 2017 Early research in Breast cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top